Arginine vasopressin for the treatment of septic shock in adults

Pharmacotherapy

Volumn 30, Issue 10, 2010, Pages 1057-1071

  Bauer, Seth R ^a   Lam, Simon W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Adrenergic agents; Antidiuretic hormone; Arginine vasopressin; AVP; Hypotension; Norepinephrine; Septic shock; Vasoconstriction; Vasopressin

Indexed keywords

ARGIPRESSIN; CATECHOLAMINE DERIVATIVE; CORTICOSTEROID; INOTROPIC AGENT; NORADRENALIN;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FLUID THERAPY; HEART ARREST; HIGH RISK PATIENT; HOMEOSTASIS; HUMAN; HYPOTENSION; KIDNEY FAILURE; MORTALITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME; UNITED STATES;

ADRENAL CORTEX HORMONES; ADULT; ARGININE VASOPRESSIN; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; HEMOSTATICS; HUMANS; NOREPINEPHRINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SHOCK, SEPTIC; TIME FACTORS; VASOCONSTRICTOR AGENTS;

EID: 77957653280     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.10.1057     Document Type: Review

References (70)

1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005;365:63-78.
2. Russell JA. Management of sepsis. N Engl J Med 2006;355: 1699-713.
3. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008;36:296-327.
4. Hollenberg SM, Ahrens TS, Annane D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 2004;32:1928-48.
5. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007;35:33-40.
6. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002. (Pubitemid 32885477)
7. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med 2004;30:1276-91. (Pubitemid 38951709)
8. Landry DW, Levin HR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
9. Obritsch MD, Bestul DJ, Jung R, Fish DN, MacLaren R. The role of vasopressin in vasodilatory septic shock. Pharmacotherapy 2004;24:1050-63. (Pubitemid 39025204)
10. Russell JA. Vasopressin in septic shock. Crit Care Med 2007;35:S609-15.
11. Szumita PM, Enfanto CM, Greenwood B, Wechsler ME. Vasopressin for vasopressor-dependent septic shock. Am J Health Syst Pharm 2005;62:1931-6.
12. Vincent JL. Vasopressin in hypotensive and shock states. Crit Care Clin 2006;22:187-97.
13. Lange M, Ertmer C, Westphal M. Vasopressin vs terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008;34:821-32. (Pubitemid 351571184)
14. Holmes CL, Walley KR. Arginine vasopressin in the treatment of vasodilatory septic shock. Best Pract Res Clin Anaesthesiol 2008;22:275-86.
15. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-87.
16. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 2010;36:83-91.
17. Russell JA, Walley KR, Gordon AC, et al. Interaction of vasopressin infusion, corticosteroid treatment, and mortality of septic shock. Crit Care Med 2009;37:811-18.
18. Russell JA, Gordon AC, Walley KR. Corticosteroids and the original vasopressin and septic shock trial subgroups. Crit Care Med 2010;38:338-9.
19. Gold JA, Hehn BP, Landry DL. Vasopressin for the treatment of septic shock [abstract]. Am J Resp Crit Care Med 1998;157: A116.
20. Malay MB, Ashton RC Jr, Landry DW, Townsend RN. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-703; discussion 703-5.
21. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
22. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-19.
23. Lauzier F, Levy B, Lamarre P, Lesur O. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. Intensive Care Med 2006;32:1782-9. (Pubitemid 44607366)
24. Torgersen C, Dunser MW, Wenzel V, et al. Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial. Intensive Care Med 2010;36:57-65.
25. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, for the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Acute renal failure: definition, outcome measures, animal models, fluid therapy and information technology needs. Crit Care 2004;8:R204-12.
26. Dunser MW, Dunser WR. Surviving sepsis campaign guidelines 2008: revisiting vasopressor recommendations [letter]. Crit Care Med 2008;36:2488; author reply 2488-9.
27. Argenziano M, Choudhri AF, Oz MC, Rose EA, Smith CR, Landry DW. A prospective randomized trial of arginine vasopressin in the treatment of vasodilatory shock after left ventricular assist device placement. Circulation 1997;96:II-286-90.
28. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416-21.
29. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-50. (Pubitemid 37455414)
30. Luckner G, Dunser MW, Jochberger S, et al. Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005;33:2659-66.
31. Luckner G, Mayr VD, Jochberger S, et al. Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007;35:2280-5.
32. Holmes CL. Vasopressin in septic shock: does dose matter? Crit Care Med 2004;32:1423-4.
33. Jochberger S, Dorler J, Luckner G, et al. The vasopressin and copeptin response to infection, severe sepsis, and septic shock. Crit Care Med 2009;37:476-82.
34. Jochberger S, Mayr VD, Luckner G, et al. Serum vasopressin concentrations in critically ill patients. Crit Care Med 2006;34:293-9. (Pubitemid 43145603)
35. Jochberger S, Morgenthaler NG, Mayr VD, et al. Copeptin and arginine vasopressin concentrations in critically ill patients. J Clin Endocrinol Metab 2006;91:4381-6. (Pubitemid 44833413)
36. Jochberger S, Velik-Salchner C, Mayr VD, et al. The vasopressin and copeptin response in patients with vasodilatory shock after cardiac surgery: a prospective, controlled study. Intensive Care Med 2009;35:489-97.
37. Lin IY, Ma HP, Lin AC, Chong CF, Lin CM, Wang TL. Low plasma vasopressin:norepinephrine ratio predicts septic shock. Am J Emerg Med 2005;23:718-24.
38. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8. (Pubitemid 36714233)
39. Lindner KH, Haak T, Keller A, Bothner U, Lurie KG. Release of endogenous vasopressors during and after cardiopulmonary resuscitation. Heart 1996;75:145-50. (Pubitemid 26068691)
40. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001;29:487-93. (Pubitemid 32225288)
41. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8.
42. Landry DW, Levin HR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
43. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamineresistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001;93:7-13.
44. Vasovski M, Browning LA, Faris J, Lau YT, Zimmerman LH. The use of vasopressin in septic patients with heart failure [abstract]. Crit Care Med 2009;37:A412.
45. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004;59:993-1001. (Pubitemid 39307237)
46. Lam SW, Bauer SR, Cha SS, Oyen LJ. Lack of an effect of body mass on the hemodynamic response to arginine vasopressin during septic shock. Pharmacotherapy 2008;28:591-9.
47. Miller JT, Alaniz C, Kraft M, Welage L. Does body weight impact the efficacy of vasopressin therapy in the management of septic shock [abstract]? Crit Care Med 2008;36:A174.
48. Bagshaw SM, Lapinsky S, Dial S, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med 2009;35:871-81.
49. Gotloib L, Barzilay E, Shustak A, Waiss Z, Lev A. Hemofiltration in severe septic adult respiratory distress syndrome associated with varicella. Intensive Care Med 1985;11:319-22. (Pubitemid 16199156)
50. Czaczkes JW, Kleeman CR, Koenig M. Physiologic studies of antidiuretic hormone by its direct measurement in human plasma. J Clin Invest 1964;43:1625-40.
51. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides 2005;26:2500-4.
52. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
53. Sutherland AM, Gordon AC, Russell JA. Are vasopressin levels increased or decreased in septic shock? Crit Care Med 2006;34:542-3.
54. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis: the ACCP/SCCM consensus conference committee, American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
55. Lam SW, Bauer. Association between catecholamine dose at the onset of arginine vasopressin for septic shock and intensive care mortality [abstract]. Crit Care Med 2009;37:A242.
56. Grinevich V, Ma XM, Jirikowski G, Verbalis J, Aguilera G. Lipopolysaccharide endotoxin potentiates the effect of osmotic stimulation on vasopressin synthesis and secretion in the rat hypothalamus. J Neuroendocrinol 2003;15:141-9. (Pubitemid 36193027)
57. Kasting NW, Mazurek MF, Martin JB. Endotoxin increases vasopressin release independently of known physiological stimuli. Am J Physiol 1985;248:E420-4.
58. Jochberger S, Zitt M, Luckner G, et al. Postoperative vasopressin and copeptin levels in noncardiac surgery patients: a prospective controlled trial. Shock 2009;31:132-8.
59. Westermann I, Dunser MW, Haas T, et al. Endogenous vasopressin and copeptin response in multiple trauma patients. Shock 2007;28:644-9.
60. Dunser MW, Hasibeder WR, Wenzel V, et al. Endocrinologic response to vasopressin infusion in advanced vasodilatory shock. Crit Care Med 2004;32:1266-71.
61. Sharshar T, Annane D. Endocrine effects of vasopressin in critically ill patients. Best Pract Res Clin Anaesthesiol 2008;22:265-73. (Pubitemid 351816778)
62. Thibonnier M, Preston JA, Dulin N, Wilkins PL, Berti-Mattera LN, Mattera R. The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology 1997;138:4109-22. (Pubitemid 27408450)
63. Aguilera G, Rabadan-Diehl C. Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul Pept 2000;96:23-9.
64. Pietranera L, Saravia F, Roig P, Lima A, De Nicola AF. Mineralocorticoid treatment upregulates the hypothalamic vasopressinergic system of spontaneously hypertensive rats. Neuroendocrinology 2004;80:100-10.
65. Kim JK, Summer SN, Wood WM, Schrier RW. Role of glucocorticoid hormones in arginine vasopressin gene regulation. Biochem Biophys Res Commun 2001;289:1252-6.
66. Kuwahara S, Arima H, Banno R, Sato I, Kondo N, Oiso Y. Regulation of vasopressin gene expression by cAMP and glucocorticoids in parvocellular neurons of the paraventricular nucleus in rat hypothalamic organotypic cultures. J Neurosci 2003;23:10231-7.
67. Lauand F, Ruginsk SG, Rodrigues HL, et al. Glucocorticoid modulation of atrial natriuretic peptide, oxytocin, vasopressin and Fos expression in response to osmotic, angiotensinergic and cholinergic stimulation. Neuroscience 2007;147:247-57. (Pubitemid 46876701)
68. Ertmer C, Bone HG, Morelli A, et al. Methylprednisolone reverses vasopressin hyporesponsiveness in ovine endotoxemia. Shock 2007;27:281-8. (Pubitemid 46272456)
69. Karmazyn M, Manku MS, Horrobin DF. Changes of vascular reactivity induced by low vasopressin concentrations: interactions with cortisol and lithium and possible involvement of prostaglandins. Endocrinology 1978;102:1230-6.
70. Bauer SR, Lam SW, Cha SS, Oyen LJ. Effect of corticosteroids on arginine vasopressin-containing vasopressor therapy for septic shock: a case control study. J Crit Care 2008;23:500-6.